Quality & complianceOfficial

Denmark flags Dacarbazine Lipomed 500 mg shortage running to end of 2027

🇩🇰 DKMA · Fri 13 Nov 2026

DKMA says Lipomed GmbH's dacarbazine 500 mg infusion powder has been in short supply since April 2026, with disruption expected through December 2027 for commercial reasons.

The Danish Medicines Agency (DKMA) has updated its supply notice for Dacarbazine "Lipomed" 500 mg powder for solution for infusion, reporting current supply problems with the product from Lipomed GmbH. The notice was first published on 19 May 2026 and revised on 13 November 2026.

According to DKMA, the expected period of disruption runs from the start of April 2026 to the end of December 2027. The agency gives the cause as commercial reasons and does not elaborate further.

The active substance is dacarbazine, which carries ATC code L01AX04. The notice does not mention alternative products, substitution advice or any measures taken by the company or the authority.

DKMA directs questions about the current status to Lipomed GmbH. The notice sits within the agency's wider section on supply notifications for medicines in Denmark.

What it means for your team

  • Hospital pharmacies and supply-chain teams in Denmark should check stock of Dacarbazine Lipomed 500 mg and plan for a disruption that DKMA expects to last until end-December 2027.
  • The notice gives no information on alternatives, so teams should contact Lipomed GmbH for current status, as DKMA advises.
  • Market-access and regulatory teams may wish to monitor DKMA's supply notifications for updates, since the notice has already been revised once.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →